Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$164.99 USD
-2.37 (-1.42%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $164.96 -0.03 (-0.02%) 7:20 PM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$164.99 USD
-2.37 (-1.42%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $164.96 -0.03 (-0.02%) 7:20 PM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
Zacks News
Agenus (AGEN) to Focus on BOT/BAL Candidate, Stock Falls 7%
by Zacks Equity Research
Agenus (AGEN) to halt all other developmental programs to focus on its BOT/BAL program. The company plans to cut its workforce by 25%.
5 Defensive Stocks to Buy Amid Lingering Market Volatility
by Ritujay Ghosh
Volatility has gripped Wall Street again. So, investing in defensive stocks like McKesson Corporation (MCK), Entergy Corporation (ETR), PepsiCo, Inc. (PEP), Johnson & Johnson (JNJ) and Atmos Energy Corporation (ATO) is a safe bet.
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for HDV
Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRW
Zoetis' (ZTS) Companion Animal Products to Boost Revenues
by Zacks Equity Research
Zoetis' (ZTS) revenues are expected to boost the pet care and livestock product sales in the quarters ahead. Disease outbreaks and potential supply challenges hurt prospects.
Will Keytruda Remain Merck's (MRK) Key Top-Line Driver?
by Zacks Equity Research
With continued label expansion into new indications, particularly earlier-line launches, Merck's (MRK) Keytruda is expected to remain a key top-line driver.
Krystal (KRYS) Up 5% on Sale of FDA's Priority Review Voucher
by Zacks Equity Research
Krystal (KRYS) announces the sale of its priority review voucher for a consideration of $100 million. The stock of the company rises 5.2% on the news.
J&J (JNJ) to Keep 9.5% Stake in Kenvue Post Share Exchange
by Zacks Equity Research
J&J's (JNJ) offer to exchange its shares for the shares of Kenvue, its recently-separated consumer healthcare business, gets oversubscribed. The exchange ratio is 8.0324 for every share of J&J.
Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why
by Zacks Equity Research
Armata Pharma (ARMP) stock skyrockets 130% in a month due to encouraging progress of the company's pathogen-targeting natural and synthetic phage candidates.
5 Blue-Chip Stocks for a Stable Portfolio Amid Volatility
by Nalak Das
We have narrowed our search to five blue-chip such stocks with strong growth potential for the rest of 2023. These are: WMT, JPM, JNJ, CAT, MCD.
Zacks Industry Outlook Highlights Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca
by Zacks Equity Research
Eli Lilly, J&J, Novo Nordisk, Novartis and AstraZeneca are part of the Zacks Industry Outlook article
Merck's (MRK) Welireg Meets Renal Cell Carcinoma Study Goals
by Zacks Equity Research
Based on interim data from a late-stage study, Merck's (MRK) Welireg achieves statistically significant improvements in one of the study's dual endpoints of progression-free survival.
Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why
by Zacks Equity Research
Belite Bio (BLTE) rises 72% in a month due to encouraging progress on the development of the company's lead product candidate Tinlarebant, which is being developed to treat several eye diseases.
Momentum Mondays: Stocks Setting up for an Epic Dip Buying Opportunity?
by Ethan Feller
Want to start the week ahead of the pack? Check out Momentum Mondays!
5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace
by Kinjel Shah
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.
Should Schwab U.S. Large-Cap Value ETF (SCHV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHV
Amphastar Pharma (AMPH) Stock Skyrockets 89% YTD: Here's Why
by Zacks Equity Research
Amphastar Pharma (AMPH) shares are up 89.1% year to date due to the acquisition of Baqsimi from Lilly. The company also receives FDA approval for Naloxone.
Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio
by Zacks Equity Research
Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.
Pharma Stock Roundup: FDA Okays PFE & JNJ Drugs, EU Approves ABBV's Migraine Drug
by Kinjel Shah
FDA approves Pfizer's (PFE) Elrexfio (elranatamab) for RRMM and J&J's (JNJ) oral combination tablet, Akeega to treat BRCA-positive mCRPC. European Commission approves AbbVie's (ABBV) Aquipta for migraine.
Here's Why it is a Good Time to Buy J&J's (JNJ) Stock Now
by Zacks Equity Research
J&J's (JNJ) Pharma sales are being driven by key drugs like Darzalex and new products. J&J's Pharma and MedTech units are likely to continue to drive sales growth in 2023.
AbbVie (ABBV) Gets EU Approval for Migraine Prevention Drug
by Zacks Equity Research
Following the approval, AbbVie's (ABBV) Aquipta is the first and the only oral CGRP receptor antagonist approved in the EU to prevent episodic and chronic migraines.
Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why
by Zacks Equity Research
Sales of Lilly's (LLY) new drug, Mounjaro are already benefiting from strong demand trends. Lilly expects regulatory decisions for some key pipeline candidates this year, which are key to growth.
Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal
by Zacks Equity Research
Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.
Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in Focus
by Zacks Equity Research
Kodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program.
Pfizer's (PFE) New Multiple Myeloma Drug Elrexfio Gets FDA Nod
by Zacks Equity Research
The FDA's accelerated approval of Pfizer's (PFE) new multiple myeloma drug Elrexfio/elranatamab is based on data from the pivotal phase II MagnetisMM-3 study.